Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CRISPR/Cas9 editing of directly reprogrammed myogenic progenitors restores dystrophin expression in a mouse model of muscular dystrophy.

Stem cell reports - 8 Feb 2022

Domenig Seraina A, Bundschuh Nicola, Lenardič Ajda, Ghosh Adhideb, Kim Inseon, Qabrati Xhem, D'Hulst Gommaar, Bar-Nur Ori

Abstract excerpt

Genetic mutations in dystrophin manifest in Duchenne muscular dystrophy (DMD), the most commonly inherited muscle disease. Here, we report on reprogramming of fibroblasts from two DMD mouse models into induced myogenic progenitor cells (iMPCs) by MyoD overexpression in concert with small molecule treatment. DMD iMPCs proliferate extensively, while expressing myogenic stem cell markers including Pax7 and Myf5....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cellular Reprogramming
Share to CRISPR-Cas Systems

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dystrophin

Share to Gene Editing

Share to Muscle Development

Share to Muscular Dystrophy, Duchenne

Share to Myoblasts

Share to MyoD Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 34995499
DOI: 10.1016/j.stemcr.2021.12.003
PMCID: PMC8828535

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CRISPR/Cas9 editing of directly reprogrammed myogenic progenitors restores dystrophin expression in a mouse model of muscular dystrophy.PMID 34995499Read ↗

A Novel CRISPR-Cas9 Strategy to Target DYSTROPHIN Mutations Downstream of Exon 44 in Patient-Specific DMD iPSCs.Semantic proximity Read ↗

In vivo genome editing in mouse restores dystrophin expression in Duchenne muscular dystrophy patient muscle fibers.Semantic proximity Read ↗

Gene Editing for Duchenne Muscular Dystrophy: From Experimental Models to Emerging TherapiesSemantic proximity Read ↗

Creation of DMD Muscle Cell Model Using CRISPR-Cas9 Genome Editing to Test the Efficacy of Antisense-Mediated Exon Skipping.Semantic proximity Read ↗

Restoration of Dystrophin Protein Expression by Exon Skipping Utilizing CRISPR-Cas9 in Myoblasts Derived from DMD Patient iPS Cells.Semantic proximity Read ↗

Induced Fetal Human Muscle Stem Cells with High Therapeutic Potential in a Mouse Muscular Dystrophy ModelSemantic proximity Read ↗

Production of Duchenne muscular dystrophy cellular model using CRISPR-Cas9 exon deletion strategy.Semantic proximity Read ↗

Methods of CRISPR/Cas9 Exon Skipping for Duchenne Muscular DystrophySemantic proximity Read ↗

CRISPR technologies for the treatment of Duchenne muscular dystrophy.Semantic proximity Read ↗

Myogenic Differentiation of Muscular Dystrophy-Specific Induced Pluripotent Stem Cells for Use in Drug DiscoverySemantic proximity Read ↗

Human induced pluripotent stem cell models for the study and treatment of Duchenne and Becker muscular dystrophiesSemantic proximity Read ↗

Correction of diverse muscular dystrophy mutations in human engineered heart muscle by single-site genome editing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.